MRKMerck Sharp & Dohme LLCSigning up patients
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
Malignant Neoplasm
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 15 (planned)
- Started
- Oct 13, 2026
- Main results expected
- Jan 2, 2034
- Fully finished
- Jan 2, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience One or More Adverse Events (AEs)
Measured over: Up to approximately 5 years
Number of Participants Who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07700758 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC